188 related articles for article (PubMed ID: 17624136)
41. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients.
Finlen Copeland CA; Snyder LD; Zaas DW; Turbyfill WJ; Davis WA; Palmer SM
Am J Respir Crit Care Med; 2010 Sep; 182(6):784-9. PubMed ID: 20508211
[TBL] [Abstract][Full Text] [Related]
42. Donor factors are associated with bronchiolitis obliterans syndrome after lung transplantation.
Hennessy SA; Hranjec T; Swenson BR; Kozower BD; Jones DR; Ailawadi G; Kron IL; Lau CL
Ann Thorac Surg; 2010 May; 89(5):1555-62. PubMed ID: 20417777
[TBL] [Abstract][Full Text] [Related]
43. Chronic lung allograft dysfunction after lung transplantation: the moving target.
Sato M
Gen Thorac Cardiovasc Surg; 2013 Feb; 61(2):67-78. PubMed ID: 23138970
[TBL] [Abstract][Full Text] [Related]
44. Status of lung transplant recipients surviving beyond five years.
Chaparro C; Scavuzzo M; Winton T; Keshavjee S; Kesten S
J Heart Lung Transplant; 1997 May; 16(5):511-6. PubMed ID: 9171269
[TBL] [Abstract][Full Text] [Related]
45. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease.
Cantu E; Appel JZ; Hartwig MG; Woreta H; Green C; Messier R; Palmer SM; Davis RD
Ann Thorac Surg; 2004 Oct; 78(4):1142-51; discussion 1142-51. PubMed ID: 15464462
[TBL] [Abstract][Full Text] [Related]
46. Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients.
Sacher VY; Fertel D; Srivastava K; Panos A; Nguyen D; Baxter T; Shafazand S; Pham SM
Ann Thorac Surg; 2014 Jan; 97(1):268-74. PubMed ID: 24119986
[TBL] [Abstract][Full Text] [Related]
47. An update on current treatment strategies for managing bronchiolitis obliterans syndrome after lung transplantation.
Arjuna A; Olson MT; Walia R; Bremner RM; Smith MA; Mohanakumar T
Expert Rev Respir Med; 2021 Mar; 15(3):339-350. PubMed ID: 33054424
[TBL] [Abstract][Full Text] [Related]
48. Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients.
Nathan SD; Barnett SD; Wohlrab J; Burton N
J Heart Lung Transplant; 2003 Apr; 22(4):427-32. PubMed ID: 12681420
[TBL] [Abstract][Full Text] [Related]
49. Elevated peptides in lung lavage fluid associated with bronchiolitis obliterans syndrome.
Stone MD; Harvey SB; Nelsestuen GL; Reilly C; Hertz MI; Wendt CH
PLoS One; 2014; 9(1):e84471. PubMed ID: 24392140
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation.
Chamberlain D; Maurer J; Chaparro C; Idolor L
J Heart Lung Transplant; 1994; 13(6):963-71. PubMed ID: 7865530
[TBL] [Abstract][Full Text] [Related]
51. The effect of bronchiolitis obliterans syndrome on health related quality of life.
Vermeulen KM; Groen H; van der Bij W; Erasmus ME; Koëter GH; TenVergert EM
Clin Transplant; 2004 Aug; 18(4):377-83. PubMed ID: 15233813
[TBL] [Abstract][Full Text] [Related]
52. A review of bronchiolitis obliterans syndrome and therapeutic strategies.
Hayes D
J Cardiothorac Surg; 2011 Jul; 6():92. PubMed ID: 21767391
[TBL] [Abstract][Full Text] [Related]
53. Impact of Forced Expiratory Volume in 1 Second (FEV1) and 6-Minute Walking Distance at 3, 6, and 12 Months and Annually on Survival and Occurrence of Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation.
Fakhro M; Ingemansson R; Algotsson L; Lindstedt S
Ann Transplant; 2017 Sep; 22():532-540. PubMed ID: 28871078
[TBL] [Abstract][Full Text] [Related]
54. Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival.
Brugière O; Pessione F; Thabut G; Mal H; Jebrak G; Lesèche G; Fournier M
Chest; 2002 Jun; 121(6):1883-9. PubMed ID: 12065353
[TBL] [Abstract][Full Text] [Related]
55. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome.
Gerbase MW; Soccal PM; Spiliopoulos A; Nicod LP; Rochat T
J Heart Lung Transplant; 2008 Aug; 27(8):898-904. PubMed ID: 18656804
[TBL] [Abstract][Full Text] [Related]
56. Health-related quality of life in post-infectious bronchiolitis obliterans: agreement between children and their proxy.
Sarria EE; Mundstock E; Mocelin HT; Fischer GB; Torres RR; Garbin JGM; Leal LF; de F Arend MHR; Stein R; Booij L; de Araújo RMF; Mattiello R
J Pediatr (Rio J); 2019; 95(5):614-618. PubMed ID: 31327498
[TBL] [Abstract][Full Text] [Related]
57. Bilateral lung transplantation for Castleman disease with end-stage bronchiolitis obliterans.
Yue B; Huang J; Jing L; Yu H; Wei D; Zhang J; Chen W; Chen J
Clin Transplant; 2022 Jan; 36(1):e14496. PubMed ID: 34590355
[TBL] [Abstract][Full Text] [Related]
58. Effects of induction immunosuppression regimen on acute rejection, bronchiolitis obliterans, and survival after lung transplantation.
Ailawadi G; Smith PW; Oka T; Wang H; Kozower BD; Daniel TM; Kron IL; Jones DR
J Thorac Cardiovasc Surg; 2008 Mar; 135(3):594-602. PubMed ID: 18329476
[TBL] [Abstract][Full Text] [Related]
59. Reliability of diagnostic criteria for bronchiolitis obliterans syndrome after lung transplantation: a survey.
Kapila A; Baz MA; Valentine VG; Bhorade SM;
J Heart Lung Transplant; 2015 Jan; 34(1):65-74. PubMed ID: 25447585
[TBL] [Abstract][Full Text] [Related]
60. Primary graft dysfunction and long-term pulmonary function after lung transplantation.
Whitson BA; Prekker ME; Herrington CS; Whelan TP; Radosevich DM; Hertz MI; Dahlberg PS
J Heart Lung Transplant; 2007 Oct; 26(10):1004-11. PubMed ID: 17919620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
